0.66
-0.0145(-2.16%)
Currency In USD
Address
171 Oyster Point Boulevard
South San Francisco, CA 94080
United States of America
Phone
650 825 6900
Sector
Healthcare
Industry
Biotechnology
Employees
97
First IPO Date
July 30, 2021
| Name | Title | Pay | Year Born |
| Mr. Faraz Ali M.B.A. | Chief Executive Officer, Interim Principal Financial Officer & Director | 890,059 | 1973 |
| Dr. Whittemore G. Tingley M.D., PH.D. | Chief Medical Officer | 645,786 | 1967 |
| Dr. Kee-Hong Kim Ph.D. | Chief Technology Officer | 0 | 1966 |
| Ms. Jennifer Drimmer J.D. | General Counsel & Corporate Secretary | 0 | N/A |
| Dr. Eric N. Olson Ph.D. | Scientific Founder & Member of Scientific Advisory Board | 0 | N/A |
| Ms. Michelle Corral | Vice President of Investor Relationship & Corporate Communications | 0 | N/A |
| Dr. Saptarsi Haldar M.D. | Scientific Founder | 0 | N/A |
| Dr. Benoit G. Bruneau Ph.D. | Scientific Founder | 0 | N/A |
| Dr. Sheng Ding Ph.D. | Scientific Founder | 0 | N/A |
| Dr. Bruce R. Conklin M.D. | Scientific Founder | 0 | N/A |
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.